$SRDX (SurModics, Inc.)

$SRDX {{ '2016-01-11T16:08:15+0000' | timeago}} • Announcement

As a result of the NorMedix transaction, $SRDX lifted FY16 revenue guidance to range of $62-66MM from previous forecast range of $60-64MM. For 2016, $SRDX lowered its EPS outlook to range of $0.30-0.35 from prior forecast of $0.38-0.43. The transaction is not expected to impact non-GAAP earnings guidance of $0.66-0.75 per share.

$JNJ {{ '2018-01-23T13:43:35+0000' | timeago}} • Announcement

$JNJ expects sales of $80.6Bil to $81.4Bil in FY18, reflecting expected operational growth in the range of 3.5% to 4.5%. Adjusted EPS for this period is estimated to be $8.00 to $8.20.

$JNJ {{ '2018-01-23T13:40:35+0000' | timeago}} • Announcement

Pharma giant $JNJ swung to a loss of $10.7Bil, or $3.99 per share in 4Q17, driven by tax-related expenses of $13.6Bil. Excluding the one-time costs, net income grew 10% to $1.74 per share. Riding on double-digit growth in drug sales during the quarter, total revenue jumped 11.5% to $20.2Bil.

$JNJ {{ '2018-01-23T13:27:16+0000' | timeago}} • Infographic

$JNJ Johnson & Johnson Earnings AlphaGraphic: Q4 2017 Highlights

$RMD {{ '2018-01-22T22:00:14+0000' | timeago}} • Announcement

Hurt by one-time charges related to the US tax reform, $RMD reported 88% decline in 2Q18 earnings to $9.5MM, or 7 cents per share. Excluding these charges, net income rose 37% to $1 during the quarter. Meanwhile, revenue jumped 13% to $601.3MM.

$RMD {{ '2018-01-22T21:48:59+0000' | timeago}} • Infographic

$RMD ResMed Inc. Earnings AlphaGraphic: Q2 2018 Highlights

$SRDX {{ '2018-01-22T14:32:58+0000' | timeago}} • Announcement

The FDA has granted approval to medical devices company $SRDX for its Telemar coronary and peripheral support microcatheter. Pursuant to the 510(K) approval, the company will start distribution of the product in the US in the coming months. The microcatheter is designed to help physicians in complex coronary and peripheral lesions.

$CELG {{ '2018-01-22T13:26:32+0000' | timeago}} • Announcement

Last week's rumor becomes reality. $CELG to acquire its strategic partner $JUNO for $9Bil. Juno Therapeutics, which had already skyrocketed nearly 50% in the last week, has increased more than 25% today in pre-market from Jan. 19th closing price of $67.81. Celgene expects that this deal will help it to boost the revenue generation beyond 2020.

$AMGN {{ '2018-01-19T13:28:13+0000' | timeago}} • Announcement

The European Commission (EC) has granted marketing authorization for MVASI from $AMGN and $AGN. MVASI is the first biosimilar bevacizumab approved by the EC and is approved for the treatment of certain types of cancers.

$AGN {{ '2018-01-17T13:14:16+0000' | timeago}} • Announcement

$AGN and $IRWD reached an agreement with Indian pharma company Sun Pharma to resolve a patent litigation for the generic version of constipation drug Linzess in the U.S. As per the agreement, Sun Pharma will be able to market the generic version of Linzess in the U.S. from Feb. 1, 2031. All the litigations related to Linzess were dismissed.

$SYK {{ '2018-01-09T17:21:37+0000' | timeago}} • Announcement

$SYK said that for 4Q17 its preliminary results are of net sales growth of 10% to $3.5Bil, while for FY17, its net sales grew 9.9% to $12.4Bil. Excluding the impact of foreign currency & acquisitions, net sales rose 8.1% and 7.1% in 4Q17 and FY17. For 2018, $SYK expects modest headwinds that will be manageable within its overall financial targets.

$HRC {{ '2018-01-09T17:07:14+0000' | timeago}} • Announcement

$HRC announced its preliminary 1Q18 revenue. For this period, the company expects worldwide revenue of approx $670MM, an increase of 5% YoY. Core revenue increased approx 2%, exceeding the company's previously issued guidance of flat core revenue growth.

$AGN {{ '2018-01-09T15:46:35+0000' | timeago}} • Announcement

$AGN, which announced its plan to give pink slips to 1,000 of its employees and cut down 400 open positions earlier this year, provided FY18 financial outlook. In 2018, Allergan plans to sell its remaining position of 10% stake in $TEVA through Forward Sale Agreements and/or open market sales.

$CELG {{ '2018-01-08T19:25:23+0000' | timeago}} • Announcement

$CELG announced preliminary results for 4Q17 and FY17. Celgene also provided the outlook for FY18 and reaffirmed FY20 guidance. The company is expected to finalize these results when it announces the earnings results on Jan. 25, 2018.

$CELG {{ '2018-01-08T14:00:46+0000' | timeago}} • Announcement

$CELG agreed to acquire start-up firm Impact Biomedicines for an upfront payment of $1.1Bil. Under the deal terms, Celgene will further pay up to $1.25Bil on Impact's cancer drug Fedratinib getting FDA's approvals. If the global annual net sales of the drug exceed $5Bil, Celgene will pay a maximum of $4.5Bil. The deal is expected to close in 1Q18.

$JNJ {{ '2018-01-02T19:20:09+0000' | timeago}} • Announcement

$JNJ declared a cash dividend for 1Q18 of $0.84 per share on the company's common stock. The dividend is payable on March 13, 2018 to shareholders as on Feb 27, 2018.

$TFX {{ '2018-01-02T14:56:01+0000' | timeago}} • Announcement

$TFX completed its senior leadership transition. Effective Jan. 1, 2018, Liam Kelly, who was previously President & COO, assumed the position of President & CEO. Mr. Kelly succeeds Benson Smith, who retired as CEO, effective Dec. 31, 2017. Mr. Smith will continue to serve as non-executive Chairman of the Board.

$AGN {{ '2017-12-26T12:22:55+0000' | timeago}} • Announcement

$AGN said that the Federal Circuit confirmed that a proposed generic version of Combigan eye drug from Sandoz, a unit of $NVS, did not infringe Allergan's two patents. The Federal Circuit also reversed the district court's decision that Sandoz's proposed generic product infringes Allergan's 3rd patent. Allergan plans to file for rehearing within 30 days.

$CELG {{ '2017-12-22T14:11:59+0000' | timeago}} • Announcement

$CELG's cancer drug Revlimid fails to meet the endpoint in the first Phase 3 trial. Celgene said that additional analyses are ongoing and it would present the complete analyzed data in a future medical conference. Revlimid contributed 63% of Celgene's revenue in their recently ended third quarter.

$JNJ {{ '2017-12-21T18:10:50+0000' | timeago}} • Announcement

Janssen Biotech, a $JNJ company, said the FDA has granted Priority Review designation for the New Drug Application (NDA) for apalutamide as treatment for non-metastatic castration-resistant prostate cancer (CRPC). This is the first agent submitted for approval to treat earlier stage castration-resistant prostate cancer at high risk for metastasis.

$AGN {{ '2017-12-21T14:38:43+0000' | timeago}} • Announcement

$AGN and its partner $PRTK announced that FDA accepted to review Seysara, an investigational drug for treating acne. Allergan, which has the U.S. rights of developing and marketing Seysara, expects FDA to take action on this in 2H18. Paratek retains the non-U.S. rights. In March 2017, Allergan announced positive results from Seysara Phase 3 trials.

Recent Transcripts

TRXC (TransEnterix, Inc.)
Thursday, November 9 2017 - 9:30pm
GMED (Globus Medical, Inc.)
Wednesday, November 8 2017 - 10:30pm
SRDX (SurModics, Inc.)
Wednesday, November 8 2017 - 1:30pm
REGN (Regeneron Pharmaceuticals, Inc.)
Wednesday, November 8 2017 - 1:30pm
CCXI (ChemoCentryx, Inc.)
Tuesday, November 7 2017 - 10:00pm
ATRS (Antares Pharma Inc.)
Tuesday, November 7 2017 - 1:30pm
HAE (Haemonetics Corporation)
Tuesday, November 7 2017 - 1:00pm
HRC (Hill-Rom Holdings, Inc.)
Friday, November 3 2017 - 12:00pm
TFX (Teleflex Incorporated)
Thursday, November 2 2017 - 12:00pm
AGN (Allergan plc)
Wednesday, November 1 2017 - 12:30pm
AMRN (Amarin Corporation plc)
Wednesday, November 1 2017 - 12:00pm
ABBV (AbbVie Inc.)
Friday, October 27 2017 - 1:00pm
SYK (Stryker Corporation)
Thursday, October 26 2017 - 8:30pm
RMD (ResMed Inc.)
Thursday, October 26 2017 - 8:30pm
CELG (Celgene Corporation)
Thursday, October 26 2017 - 1:00pm
BIIB (Biogen Inc.)
Tuesday, October 24 2017 - 12:30pm
ABT (Abbott Laboratories)
Wednesday, October 18 2017 - 1:00pm
JNJ (Johnson & Johnson)
Tuesday, October 17 2017 - 12:30pm
CCXI (ChemoCentryx, Inc.)
Tuesday, August 8 2017 - 9:00pm
ATRS (Antares Pharma Inc.)
Tuesday, August 8 2017 - 12:30pm

AlphaGraphics you may like